Larotrectinib Exhibits Sustained Efficacy and Favorable Safety in TRK Fusion Lung Cancer
June 6th 2022
Rapid onset and sustained responses translating to extended survival and a favorable toxicity profile were seen with larotrectinib in patients with advanced lung cancer harboring NTRK gene fusions, including in those with central nervous system metastases, according to results from an expanded cohort.